Last reviewed · How we verify
NCT06764082
Nutritional Intervention for Biliary Atresia
NA trial testing high MCT formula in Nutrition Disorder, Infant in 120 participants. Currently enrolling.
30 June 2028
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 February 2025 |
| Primary completion | 30 June 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- high MCT formula
- normal oral intake of the traditional formula
Conditions studied
- Nutrition Disorder, Infant — all drugs for Nutrition Disorder, Infant →
- Biliary Atresia — all drugs for Biliary Atresia →
Sponsor
Tongji Hospital
Who can join
Adults 1 Day to 3 Months, any sex, with Nutrition Disorder, Infant or Biliary Atresia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Infants with biliary atresia (Biliary atresia, BA) have an increased risk of malnutrition due to insufficient dietary intake to maintain normal growth, impaired intestinal absorption, increased metabolic rate, and damage to some liver macronutrient metabolic pathways. The medium-chain triglyceride formula (MCT) in enteral nutrition has advantages: (1) It has a fast metabolism in the liver and possesses the advantage of being an innate energy source; (2) It can share metabolic pathways with some other fatty acids (DHA, EPA), and can promote the synthesis of phospholipids, etc. Therefore, EN containing the MCT formula is regarded as an important approach to alleviate growth retardation in BA children and improve the nutritional status of patients. This study aims to observe the effect of intensified enteral feeding with a high MCT formula during the perioperative period compared to traditional oral feeding on the prognosis of children with biliary atresia. The method adopted is a prospective, two-arm, open-label, multicenter, and interventional real-world study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06764082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nutrition Disorder, Infant
Currently open trials in the same condition.
- NCT04599010 — Role of Body Composition in Large for Gestational Age Infants (LGA) With Oral Feeding Difficulty · NA · recruiting
- NCT04447742 — Bern Birth Cohort / Trajectory of Microbiota Maturation in Healthy Bern Infants - a Network Approach · recruiting
- NCT03977259 — Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development · NA · active not recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06764082 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 22 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06764082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing